Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth

KRAS is the most frequently mutated oncogene in human tumors, and its activating mutations represent important therapeutic targets. The combination of Cas9 and guide RNA from the CRISPR-Cas system recognizes a specific DNA sequence and makes a double-strand break, which enables editing of the releva...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Wonjoo, Lee, Sangeun, Kim, Han Sang, Song, Minjung, Cha, Yong Hoon, Kim, Young-Hoon, Shin, Jeonghong, Lee, Eun-Seo, Joo, Yeonsoo, Song, Jae J., Choi, Eun Ju, Choi, Jae W., Lee, Jinu, Kang, Moonkyung, Yook, Jong In, Lee, Min Goo, Kim, Yeon-Soo, Paik, Soonmyung, Kim, Hyongbum (Henry)
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2018
Materias:
Method
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848616/
https://www.ncbi.nlm.nih.gov/pubmed/29326299
http://dx.doi.org/10.1101/gr.223891.117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848616/
https://www.ncbi.nlm.nih.gov/pubmed/29326299
http://dx.doi.org/10.1101/gr.223891.117

Ejemplares similares